Accure Therapeutics

Oculis S.A. missed statistical significance in most signs of dry eye disease in the 122-patient RELIEF study of licaminlimab (OCS-2), but the trial did reach statistical significance in a biomarker-i

Fresh from completing its merger with a special purpose acquisition corporation (SPAC), Oculis S.A. can once again focus on the clinical progress of its eye disease pipeline. The Swiss biotech says

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seeking To Replicate Vraylar Success, A